News & Events
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
Crinetics announced today that it intends to offer and sell, subject to market and other conditions, $250.0 million of shares...
READ MORECrinetics Topline Results from Paltusotine Phase 3 PATHFNDR-1 Study
Event Date: September 11, 2023
READ MORECrinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-1 Study Evaluating Treatment of Patients with Acromegaly
Crinetics Pharmaceuticals reports that paltusotine, an oral, once-daily investigational compound, met the primary endpoint and all secondary endpoints of the...
READ MORECrinetics Announces September 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals announces September 2023 inducement grants: the stock options were granted as inducements material to nine employees entering into...
READ MORECrinetics Announces August 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals announces August 2023 inducement grants: the stock options were granted as inducements material to seven employees entering into...
READ MORECrinetics Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Crinetics Pharmaceuticals reported financial results and provided an update on second quarter 2023 progress
READ MORECrinetics Hosting Key Opinion Leader Webinar to Discuss the Current Treatment Landscape and Unmet Need in Acromegaly
Crinetics Pharmaceuticals is hosting a webinar on the acromegaly treatment landscape and unmet need with KOLs Beverly MK Biller M.D....
READ MOREKOL Webinar on Current Treatment Landscape and Unmet Medical Need in Acromegaly
Event Date: August 8, 2023
READ MORECrinetics Announces July 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals announces July 2023 inducement grants: the stock options were granted as inducements material to 10 employees entering into...
READ MORENew Data Demonstrating Stable Biochemical and Symptom Levels with Two-Years of Oral Paltusotine Administration Presented at ENDO 2023
Data from the Crinetics Phase 2 Advance study of oral paltusotine was presented at ENDO 2023, along with proof-of-concept data...
READ MORETransforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine-rooted care.
Email Signup
Please click CONTINUE below to learn more about a new treatment option. This website contains information about a prescription medicine.